Abstract
Background:
We used data from the Michigan Urological Surgery Improvement Collaborative (MUSIC) to investigate the use of adjuvant and salvage radiotherapy (ART, SRT) among patients with high-risk pathology following radical prostatectomy (RP).
Methods:
For patients with pT3a disease or higher and/or positive surgical margins, we examined post-RP radiotherapy administration across MUSIC practices. We excluded patients with <6 months follow-up, and those that failed to achieve a postoperative PSA nadir ⩽0.1. ART was defined as radiation administered within 1 year post RP, with all post-nadir PSA levels <0.1 ng ml−1. Radiation administered >1 year post RP and/or after a post-nadir PSA ⩾0.1 ng ml−1 was defined as SRT. We used claims data to externally validate radiation administration.
Results:
Among 2337 patients undergoing RP, 668 (28.6%) were at high risk of recurrence. Of these, 52 (7.8%) received ART and 56 (8.4%) underwent SRT. Patients receiving ART were younger (P=0.027), more likely to have a greater surgical Gleason sum (P=0.009), higher pathologic stage (P<0.001) and received treatment at the smallest and largest size practices (P=0.011). Utilization of both ART and SRT varied widely across MUSIC practices (P<0.001 and P=0.046, respectively), but practice-level rates of ART and SRT administration were positively correlated (P=0.003) with lower ART practices also utilizing SRT less frequently. Of the 88 patients not receiving ART and experiencing a PSA recurrence ⩾0.2 ng ml−1, 38 (43.2%) progressed to a PSA ⩾0.5 ng ml−1 and 20 (22.7%) to a PSA ⩾1.0 ng ml−1 without receiving prior SRT. There was excellent concordance between registry and claims data κ=0.98 (95% CI: 0.94–1.0).
Conclusions:
Utilization of ART and SRT is infrequent and variable across urology practices in Michigan. Although early SRT is an alternative to ART, it is not consistently utilized in the setting of post-RP biochemical recurrence. Quality improvement initiatives focused on current postoperative radiotherapy administration guidelines may yield significant gains for this high-risk population.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 4 print issues and online access
$259.00 per year
only $64.75 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Wiegel T, Bartkowiak D, Bottke D, Bronner C, Steiner U, Siegmann A et al. Adjuvant radiotherapy versus wait-and-see after radical prostatectomy: 10-year follow-up of the ARO 96-02/AUO AP 09/95 trial. Eur Urol 2014; 66: 243–250.
Bolla M, Van Poppel H, Tombal B, Vekemans K, Da Pozzo L, De Reijke TM et al. Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911). Lancet 2012; 380: 2018–2027.
Thompson IM, Tangen CM, Paradelo J, Lucia MS, Miller G, Troyer D et al. Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial. J Urol 2009; 181: 956–962.
Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, Van Der Kwast T et al. EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 2014; 65: 467–479.
Thompson IM, Valicenti RK, Albertsen P, Davis BJ, Goldenberg SL, Hahn C et al. Adjuvant and salvage radiotherapy after prostatectomy: AUA/ASTRO guideline. J Urol 2013; 190: 441–449.
Kalbasi A, Swisher-Mcclure S, Mitra N, Sunderland R, Smaldone MC, Uzzo RG et al. Low rates of adjuvant radiation in patients with nonmetastatic prostate cancer with high-risk pathologic features. Cancer 2014; 120: 3089–3095.
Montie JE, Linsell SM, Miller DC . Quality of care in urology and the Michigan urological surgery improvement collaborative. Urol Pract 2014; 1: 74–78.
Womble PR, Montie JE, Ye Z, Linsell SM, Lane BR, Miller DC . Contemporary use of initial active surveillance among men in Michigan with low-risk prostate cancer. Eur Urol 2015; 67: 44–50.
Womble PR, Dixon MW, Linsell SM, Ye Z, Montie JE, Lane BR et al. Infection related hospitalizations after prostate biopsy in a statewide quality improvement collaborative. J Urol 2014; 191: 1787–1792.
Riedinger CB, Womble PR, Linsell SM, Ye Z, Montie JE, Miller DC et al. Variation in prostate cancer detection rates in a statewide quality improvement collaborative. J Urol 2014; 192: 373–378.
Schroeck FR, Kaufman SR, Jacobs BL, Zhang Y, Weizer AZ, Montgomery JS et al. The impact of technology diffusion on treatment for prostate cancer. Med Care 2013; 51: 1076–1084.
Sineshaw HM, Gray PJ, Efstathiou JA, Jemal A . Declining use of radiotherapy for adverse features after radical prostatectomy: results from the National Cancer Data Base. Eur Urol 2015; 68: 768–774.
Hoffman KE, Nguyen PL, Chen MH, Chen RC, Choueiri TK, Hu JC et al. Recommendations for post-prostatectomy radiation therapy in the United States before and after the presentation of randomized trials. J Urol 2011; 185: 116–120.
Gandaglia G, Karakiewicz PI, Briganti A, Trudeau V, Trinh Q-D, Kim SP et al. Early radiotherapy after radical prostatectomy improves cancer-specific survival only in patients with highly aggressive prostate cancer: validation of recently released criteria. Int J Urol 2015; 22: 89–95.
Trock BJ, Han M, Freedland SJ, Humphreys EB, Deweese TL, Partin AW et al. Prostate cancer-specific survival following salvage radiotherapy vs observation after radical prostatectomy. JAMA 2008; 299: 2760–2769.
Boorjian SA, Karnes RJ, Crispen PL, Rangel LJ, Bergstralh EJ, Blute ML . Radiation therapy after radical prostatectomy: impact on metastasis and survival. J Urol 2009; 182: 2708–2715.
Thompson IM, Tangen CM, Paradelo J, Lucia MS, Miller G, Swanson G et al. Adjuvant radiotherapy for pathologically advanced prostate cancer. JAMA 2006; 296: 2329–2335.
Bolla M, Van Poppel H, Collette L, Van Cangh P, Vekemans K, Da Pozzo L et al. Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet 2005; 366: 572–578.
Wiegel T, Bottke D, Steiner U, Siegmann A, Golz R, Störkel S et al. Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95. J Clin Oncol 2009; 27: 2924–2930.
Parker C, Clarke N, Logue J, Payne H, Catton C, Kynaston H et al. RADICALS (Radiotherapy and Androgen Deprivation in Combination after Local Surgery). Clin Oncol 2007; 19: 167–171.
Pearse M, Fraser-Browne C, Davis ID, Duchesne GM, Fisher R, Frydenberg M et al. A phase III trial to investigate the timing of radiotherapy for prostate cancer with high-risk features: background and rationale of the Radiotherapy— Adjuvant Versus Early Salvage (RAVES) trial. BJU Int 2014; 113: 7–12.
Pfister D, Bolla M, Briganti A, Carroll P, Cozzarini C, Joniau S et al. Early salvage radiotherapy following radical prostatectomy. Eur Urol 2014; 65: 1034–1043.
Hsu CC, Paciorek AT, Cooperberg MR, Roach M, Hsu I-CJ, Carroll PR . Postoperative radiation therapy for patients at high-risk of recurrence after radical prostatectomy: does timing matter? BJU Int 2015; 116: 713–720.
Stephenson AJ, Scardino PT, Kattan MW, Pisansky TM, Slawin KM, Klein EA et al. Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol 2007; 25: 2035–2041.
Perez BA, Koontz BF . Radiotherapy before and after radical prostatectomy for high-risk and locally advanced prostate cancer. Urol Oncol Semin Orig Investig 2014; 33: 226–234.
Kim SP, Tilburt JC, Karnes RJ, Ziegenfuss JY, Han LC, Shah ND et al. Variation in treatment recommendations of adjuvant radiation therapy for high-risk prostate cancer by physician specialty. Urology 2013; 82: 807–812.
Den RB, Yousefi K, Trabulsi EJ, Abdollah F, Choeurng V, Feng FY et al. Genomic classifier identifies men with adverse pathology after radical prostatectomy who benefit from adjuvant radiation therapy. J Clin Oncol 2015; 33: 944–1416.
Den RB, Feng FY, Showalter TN, Mishra MV, Trabulsi EJ, Lallas CD et al. Genomic prostate cancer classifier predicts biochemical failure and metastases in patients after postoperative radiation therapy. Int J Radiat Oncol Biol Phys 2014; 89: 1038–1046.
Acknowledgements
Michigan Urological Surgery Improvement Collaborative (MUSIC) is funded by Blue Cross Blue Shield of Michigan (BCBSM). BCBSM provided funding for the collection and management of the data, but had no role in the design and conduct of the study, the analysis and interpretation of the data, the preparation, review or approval of the manuscript, or the decision to submit the manuscript for publication. We acknowledge the significant contribution of the clinical champions, urologists and data abstractors in each participating MUSIC practice (details around specific participating urologists and practices can be found at www.musicurology.com). In addition, we acknowledge the support provided by the Value Partnerships program at BCBSM. We also acknowledge the contributions of the Michigan Data Collaborative for their compilation of the claims data necessary for the validation processes. This work was supported by Blue Cross Blue Shield of Michigan. TMM is supported by the Department of Defense Physician Research Training Award (W81XWH-14-1-0287), Prostate Cancer Foundation Young Investigator Award and by the Alfred A. Taubman Institute.
Author information
Authors and Affiliations
Consortia
Corresponding author
Ethics declarations
Competing interests
TMM is a consultant/advisor for and receives research funding from Myriad Genetics. KRG is a consultant/advisor for Lumenis and Boston Scientific, and receives salary support from Blue Cross Blue Shield of Michigan as the co-director of the Michigan Urological Surgery Improvement Collaborative. DCM receives salary support from Blue Cross Blue Shield of Michigan as the director of the Michigan Urological Surgery Improvement Collaborative and the Michigan Value Collaborative. FYF has a leadership role at PFS Genomics, is a consultant/advisor for Medivation/Astellas, GenomeDx Biosciences and Celgene, and has research funding from Varian, Celgene and Medivation/Astellas. JEM is a consultant/advisor for and has ownership in Histosonics. MLC was part of Astellas-Medivation speaker’s bureau. The remaining authors declare no conflict of interest.
Additional information
This study was presented at the 2015 American Urological Association annual meeting.
Supplementary Information accompanies the paper on the Prostate Cancer and Prostatic Diseases website
Supplementary information
Rights and permissions
About this article
Cite this article
Morgan, T., Hawken, S., Ghani, K. et al. Variation in the use of postoperative radiotherapy among high-risk patients following radical prostatectomy. Prostate Cancer Prostatic Dis 19, 216–221 (2016). https://doi.org/10.1038/pcan.2016.9
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/pcan.2016.9
This article is cited by
-
Immediate radiotherapy versus observation in patients with node-positive prostate cancer after radical prostatectomy
Prostate Cancer and Prostatic Diseases (2022)
-
Salvage therapy for prostate cancer after radical prostatectomy
Nature Reviews Urology (2021)
-
Prediction of biochemical failure using prostate-specific antigen half-life in patients with adverse pathologic features after radical prostatectomy
World Journal of Urology (2019)
-
Adjuvant Versus Early Salvage Radiation Therapy Following Radical Prostatectomy for Men with Localized Prostate Cancer
Current Urology Reports (2017)